Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ostroff: Administration Coming Up To Speed On Planned FDA Guidances

Executive Summary

There’s been a dearth of guidances from US FDA since Donald Trump's inauguration, but the acting FDA commissioner says that simply reflects the new administration catching up on what's in the pipeline. In a speech at FDLI's annual meeting, Stephen Ostroff struck a positive tone.

You may also be interested in...



Gottlieb Becomes FDA Commissioner With Immediate Issues Pending

Confirmation comes with fewest votes of any recent commissioner as FDA faces pressing budget, user-fee and other issues. The Personal Care Products Council welcomed Gottlieb to the post and took the occasion to plug cosmetics industry virtues at a time when legislation is under consideration to update regulations.

Gottlieb Becomes US FDA Commissioner With Immediate Issues Pending

Senate confirmation includes fewest supporting votes for any candidate ever as agency tackles budget, user fees and other issues.

Current FDA Policy Uncertainties Could Yield 'Reverse Impact' Of Support

At FDLI, both US FDA acting Commissioner Stephen Ostroff and BIO’s Kay Holcombe strike note of anticipating positive outcomes for FDA, despite current political and regulatory uncertainties. FDA has been through challenges before, and “we have come through them even stronger," Ostroff assures meeting.

Related Content

Topics

UsernamePublicRestriction

Register

PS120575

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel